卵巢癌女性的失眠及其与生活质量的关系
OPAL前瞻性研究纳入894名澳大利亚上皮性卵巢癌女性,在诊断后3、6、9、12、24、36个月评估失眠症状、用药与生活质量。诊断后三年内约四分之一报告临床失眠症状,另有13%规律使用助眠药物(共36%受影响);临床失眠者同期生活质量低8.4分(95%CI:7.2-9.5),3个月后低5.5分(95%CI:3.4-7.6)。
要点
- 诊断后三年内约四分之一卵巢癌女性报告符合临床失眠的症状。
- 另有13%规律使用助眠药物,合计36%受失眠影响。
- 临床失眠者同期及3个月后生活质量均显著低于无失眠者。
核心结论
- 超过三分之一的卵巢癌女性诊断后可能经历失眠,失眠可能持续并与较差的生活质量相关。
研究设计与样本
- OPAL(卵巢癌、预后与生活方式)是对澳大利亚上皮性卵巢癌女性的前瞻性研究。
- 894名女性在诊断后3、6、9、12、24和36个月提供了失眠症状、药物及生活质量信息。
- 采用广义线性混合模型分析失眠与同期及3个月后生活质量的关系。
主要发现
- 诊断后三年内约四分之一女性报告符合临床失眠的症状,另有13%规律使用助眠药物,合计36%受影响。
- 排除诊断前已有失眠症状的7%后,22%报告新发失眠;进一步排除化疗中的女性后降至17%。
- 诊断后3个月时临床失眠(14%)或亚临床失眠(28%)症状的比例最高。
- 与无失眠女性相比,临床失眠者同期生活质量低8.4分(95%CI:7.2-9.5),3个月后低5.5分(95%CI:3.4-7.6),均显著较低。
关键数值与推荐
- 临床失眠者较无失眠者生活质量评分低8.4分(95%CI:7.2-9.5)。
- 临床失眠者较无失眠者3个月后生活质量评分低5.5分(95%CI:3.4-7.6)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Insomnia is common in women with ovarian cancer but there are limited prospective data on the frequency and degree of impact on patients. Our objective was to determine the prevalence of insomnia over the first three years after a diagnosis of ovarian cancer; and the relationship between insomnia and quality of life. METHODS: OPAL (Ovarian cancer, Prognosis And Lifestyle) is a prospective study of Australian women with epithelial ovarian cancer; 894 provided information on insomnia symptoms, medications and quality of life at three, six, nine, 12, 24 and 36 months after diagnosis. Generalised linear mixed models were used to determine the relationship between insomnia and quality of life measured at the same time and three months later. RESULTS: One-quarter of women reported symptoms consistent with clinical insomnia within three years after diagnosis and an additional 13% regularly used sleep medication (total 36% affected). Excluding 7% who reported insomnia symptoms before diagnosis, 22% reported new insomnia, which reduced to 17% when also excluding women on chemotherapy. The proportion of women with clinical (14%) or subclinical (28%) insomnia symptoms was highest at three months after diagnosis. Compared to women with no insomnia, those with clinical insomnia had significantly lower quality of life measured at the same time (8.4 points lower, 95% CI: 7.2-9.5), and three months later (5.5 points lower, 95% CI: 3.4-7.6). CONCLUSIONS: Over a third of women with ovarian cancer likely experience insomnia after diagnosis; this may persist and is associated with poorer quality of life.
引用
- Ross TL, DeFazio A, Friedlander M, et al. Insomnia and its association with quality of life in women with ovarian cancer. Gynecol Oncol. 2020. PMID: 32653100. doi:10.1016/j.ygyno.2020.06.500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。